drugset / Trial / NCT05182073
FT576 in Subjects With Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Timeline
- Start
- 2021-11-10
- Primary completion
- 2024-09-20
- Completion
- 2024-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | FT576 | Cell therapy | — | — |
| Background | Bendamustine | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |